<div id="readability-page-1"><ul><li>MaxCyte: Building the Future of Cell and Gene Therapy Innovation</li></ul><p>MaxCyte, Inc. (NASDAQ:MXCT - Free Report) - Stock analysts at William Blair upped their FY2025 earnings per share estimates for MaxCyte in a report released on Thursday, November 13th. William Blair analyst M. Larew now forecasts that the company will post earnings of ($0.39) per share for the year, up from their prior estimate of ($0.46). William Blair currently has a &#34;Market Perform&#34; rating on the stock. The consensus estimate for MaxCyte's current full-year earnings is ($0.42) per share. William Blair also issued estimates for MaxCyte's Q4 2025 earnings at ($0.07) EPS, Q1 2026 earnings at ($0.06) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.27) EPS.</p><p>MaxCyte (NASDAQ:MXCT - Get Free Report) last released its earnings results on Wednesday, November 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). The firm had revenue of $6.41 million during the quarter, compared to analyst estimates of $8.37 million. MaxCyte had a negative net margin of 125.22% and a negative return on equity of 22.12%. </p><p>A number of other equities analysts also recently commented on the stock. BTIG Research  reiterated a &#34;neutral&#34; rating on shares of MaxCyte in a research note on Monday, August 11th. Wall Street Zen cut shares of MaxCyte from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, August 9th. Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of MaxCyte in a report on Tuesday, November 11th. Finally, Stephens started coverage on shares of MaxCyte in a research report on Tuesday, July 22nd. They issued an &#34;overweight&#34; rating and a $6.00 price target for the company. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one  has assigned  a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $7.00.</p><p><b>Read Our Latest Research Report on MXCT</b></p><h2>MaxCyte Price Performance</h2><p>Shares of NASDAQ MXCT opened at $1.58 on Monday. The stock's 50-day moving average is $1.58 and its two-hundred day moving average is $1.88. MaxCyte has a 1-year low of $1.26 and a 1-year high of $5.20. The company has a market cap of $168.44 million, a price-to-earnings ratio of -3.67 and a beta of 1.23. </p><h2>Institutional Inflows and Outflows</h2><p>A number of institutional investors and hedge funds have recently bought and sold shares of MXCT. Bridgeway Capital Management LLC increased its holdings in shares of  MaxCyte by 44.6% in the 3rd quarter. Bridgeway Capital Management LLC now owns 180,800 shares of the company's stock valued at $286,000 after purchasing an additional 55,800 shares in the last quarter.  Kennedy Capital Management LLC purchased a new position in  MaxCyte in the 3rd quarter valued at approximately $3,330,000.  UBS Group AG raised its holdings in  MaxCyte by 186.3% during the third quarter. UBS Group AG now owns 474,487 shares of the company's stock worth $750,000 after purchasing an additional 308,769 shares during the last quarter.  BNP Paribas Financial Markets grew its stake in  MaxCyte by 39.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 36,271 shares of the company's stock valued at $57,000 after acquiring an additional 10,263 shares during the last quarter.  Finally, Willis Investment Counsel grew its position in shares of  MaxCyte by 126.8% in the third quarter. Willis Investment Counsel now owns 862,758 shares of the company's stock valued at $1,363,000 after purchasing an additional 482,287 shares during the last quarter. Institutional investors and hedge funds own  68.81% of the company's stock. </p><h2>About MaxCyte</h2> (Get Free Report)<p>MaxCyte, Inc, a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than MaxCyte</li><li>3 Home Improvement Stocks that Can Upgrade Your Portfolio</li><li>4 Cold-Weather Stocks to Buy as Winter Spending Heats Up</li><li>The Most Important Warren Buffett Stock for Investors: His Own</li><li>Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?</li><li>2 Rising CRM Platform Stocks That Can Surge Higher in 2025 </li><li>Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?</li></ul> <p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVhDVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TVhDVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in MaxCyte Right Now?</h2><p>Before you consider MaxCyte, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MaxCyte wasn't on the list.</p><p>While MaxCyte currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MXCT

<p>William Blair has increased its FY2025 EPS estimates for MaxCyte from ($0.46) to ($0.39) per share. The firm maintains a "Market Perform" rating on the stock. MaxCyte's recent earnings missed consensus estimates, reporting ($0.12) EPS against an expected ($0.11). The stock has a consensus rating of "Hold" with a target price of $7.00. Institutional investors have been actively trading MaxCyte shares, with significant inflows and outflows noted in the third quarter.</p>

FY2025 EPS Estimates for MaxCyte Boosted by William Blair